Literature DB >> 36098799

Phosphatidylserine Regulation of Coagulation Proteins Factor IXa and Factor VIIIa.

Rinku Majumder1.   

Abstract

Blood coagulation is an intricate process, and it requires precise control of the activities of pro- and anticoagulant factors and sensitive signaling systems to monitor and respond to blood vessel insults. These requirements are fulfilled by phosphatidylserine, a relatively miniscule-sized lipid molecule amid the myriad of large coagulation proteins. This review limelight the role of platelet membrane phosphatidylserine (PS) in regulating a key enzymatic reaction of blood coagulation; conversion of factor X to factor Xa by the enzyme factor IXa and its cofactor factor VIIIa. PS is normally located on the inner leaflet of the resting platelet membrane but appears on the outer leaflet surface of the membrane surface after an injury happens. Human platelet activation leads to exposure of buried PS molecules on the surface of the platelet-derived membranes and the exposed PS binds to discrete and specific sites on factors IXa and VIIIa. PS binding to these sites allosterically regulates both factors IXa and VIIIa. The exposure of PS and its binding to factors IXa/VIIIa is a vital step during clotting. Insufficient exposure or a defective binding of PS to these clotting proteins is responsible for various hematologic diseases which are discussed in this review.
© 2022. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.

Entities:  

Keywords:  Coagulation; Factor IXa; Factor Xa; Phosphatidylserine; Protein S

Year:  2022        PMID: 36098799     DOI: 10.1007/s00232-022-00265-7

Source DB:  PubMed          Journal:  J Membr Biol        ISSN: 0022-2631            Impact factor:   2.426


  41 in total

Review 1.  Vitamin K-dependent biosynthesis of gamma-carboxyglutamic acid.

Authors:  B Furie; B A Bouchard; B C Furie
Journal:  Blood       Date:  1999-03-15       Impact factor: 22.113

Review 2.  The coagulation cascade: initiation, maintenance, and regulation.

Authors:  E W Davie; K Fujikawa; W Kisiel
Journal:  Biochemistry       Date:  1991-10-29       Impact factor: 3.162

3.  Decreased platelet surface phosphatidylserine predicts increased bleeding in patients with severe factor VIII deficiency.

Authors:  Stacy E Croteau; Andrew L Frelinger; Anja J Gerrits; Alan D Michelson
Journal:  J Thromb Haemost       Date:  2021-03-07       Impact factor: 5.824

Review 4.  Major bleeding disorders: diagnosis, classification, management and recent developments in haemophilia.

Authors:  Neha Bhatnagar; Georgina W Hall
Journal:  Arch Dis Child       Date:  2017-11-25       Impact factor: 3.791

5.  Activation of the factor VIIIa-factor IXa enzyme complex of blood coagulation by membranes containing phosphatidyl-L-serine.

Authors:  G E Gilbert; A A Arena
Journal:  J Biol Chem       Date:  1996-05-10       Impact factor: 5.157

6.  Human factor VIIIa subunit structure. Reconstruction of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit.

Authors:  P J Fay; P J Haidaris; T M Smudzin
Journal:  J Biol Chem       Date:  1991-05-15       Impact factor: 5.157

7.  Specificity of soluble phospholipid binding sites on human factor Xa.

Authors:  Mou Banerjee; Daryl C Drummond; Arvind Srivastava; David Daleke; Barry R Lentz
Journal:  Biochemistry       Date:  2002-06-18       Impact factor: 3.162

8.  Specific membrane binding of factor VIII is mediated by O-phospho-L-serine, a moiety of phosphatidylserine.

Authors:  G E Gilbert; D Drinkwater
Journal:  Biochemistry       Date:  1993-09-21       Impact factor: 3.162

9.  Phosphatidylethanolamine induces high affinity binding sites for factor VIII on membranes containing phosphatidyl-L-serine.

Authors:  G E Gilbert; A A Arena
Journal:  J Biol Chem       Date:  1995-08-04       Impact factor: 5.157

10.  Discordant fibrin formation in hemophilia.

Authors:  K E Brummel-Ziedins; R F Branda; S Butenas; K G Mann
Journal:  J Thromb Haemost       Date:  2009-01-28       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.